Olaparib inhibits oxLDL-induced increase in NF-κB activity.

Abstract

The THP-1 monocytes were exposed to oxLDL, the PARP inhibitor olaparib (Olapa), or the NLRP3 inhibitor MCC950 (MCC) as indicated. The cell lysates were subjected to SDS-PAGE and immunoblotted with anti-IKK-α (top), anti-phospho-IκBα (middle) or anti-vinculin antibody (bottom, for loading control), as indicated. The band densities, relative to vinculin, were quantified using ImageJ (NIH, Bethesda, MD). N = 4/group, *P<0.05 vs vehicle, #P<0.05 vs oxLDL only, one-way ANOVA, Newman-Keuls test.</p